MINIPRESS XL Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Minipress Xl, and when can generic versions of Minipress Xl launch?

Minipress Xl is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in MINIPRESS XL is prazosin hydrochloride. There are seventeen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the prazosin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Minipress Xl

A generic version of MINIPRESS XL was approved as prazosin hydrochloride by TEVA PHARMS on September 12^th, 1988.

Try a Trial

Summary for MINIPRESS XL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	117
Clinical Trials:	27
Patent Applications:	1,782
Formulation / Manufacturing:	see details
DailyMed Link:	MINIPRESS XL at DailyMed

Drug patent expirations by year for MINIPRESS XL

Recent Clinical Trials for MINIPRESS XL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yale University	Phase 1/Phase 2
University of Washington	Phase 4
Johns Hopkins University	Phase 2

See all MINIPRESS XL clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for MINIPRESS XL

C02CA	Alpha-adrenoreceptor antagonists
C02C	ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
C02	ANTIHYPERTENSIVES
C	Cardiovascular system

US Patents and Regulatory Information for MINIPRESS XL

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-001	Jan 29, 1992		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-002	Jan 29, 1992		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for MINIPRESS XL

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-001	Jan 29, 1992	⤷ Try a Trial	⤷ Try a Trial
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-001	Jan 29, 1992	⤷ Try a Trial	⤷ Try a Trial
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-001	Jan 29, 1992	⤷ Try a Trial	⤷ Try a Trial
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-001	Jan 29, 1992	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for MINIPRESS XL

See the table below for patents covering MINIPRESS XL around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Japan	S6043045		⤷ Try a Trial
Japan	H0575725		⤷ Try a Trial
Austria	397180		⤷ Try a Trial
Japan	S52105206	NOVEL CRYSTAL FORM OF 224422FROYLPIPERAZINEE11IL44AMINOO6 77DIMETHOXYCHINAZOLIN HYDROCHLORIDE	⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Summary for MINIPRESS XL

Recent Clinical Trials for MINIPRESS XL

Anatomical Therapeutic Chemical (ATC) Classes for MINIPRESS XL

Make Better Decisions: Try a trial or see plans & pricing